Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.58 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6032677 | 0.98 | MKNK1 (0.60) | MKNK1MKNK2CDC7MAPK11MAPK14 | |
| SCHEMBL27696604 | 0.84 | POLB (0.51) | MKNK1MKNK2MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL3881594 | 0.83 | POLB (0.50) | MKNK1MKNK2MEN1KMT2APOLB | |
| SCHEMBL20134937 | 0.82 | SMN1; SMN2 (0.49) | MKNK1MKNK2MEN1KMT2ACHEK1 | |
| SCHEMBL2755249 | 0.82 | MKNK1 (0.49) | MKNK1MKNK2MEN1KMT2APOLB | |
| SCHEMBL31601884 | 0.81 | ALDH1A1 (0.51) | MKNK1MKNK2PKN2PIM1 | |
| SCHEMBL31601724 | 0.81 | HTR2C (0.53) | MKNK1MKNK2MEN1KMT2APOLB | |
| SCHEMBL31601661 | 0.81 | ALDH1A1 (0.51) | MKNK1MKNK2PKN2PIM1 | |
| SCHEMBL31601739 | 0.80 | TLR7 (0.47) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL31601793 | 0.80 | MKNK1 (0.45) | MKNK1MKNK2CDC7TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| CN-1809354-A | Inhibitors of Akt activity | MERCK & CO INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1622616-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096131-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | MKNK1 22/4885MKNK2 21/4885CDC7 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.